Isoxazole compounds as histamine H 3 modulators

Details Isoxazole compounds as histamine H 3 modulators Isoxazole compounds as histamine H 3 modulators

2011-05-24

2011-05-24

Jarrell, Noble (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S240000, C548S243000, C548S244000, C548S245000, C548S246000, C548S247000, C548S248000

Reexamination Certificate

active

07947718

ABSTRACT:
Certain isoxazole compounds are histamine H3modulators useful in the treatment of histamine H3receptor mediated diseases.

REFERENCES:
patent: 3538106 (1970-11-01), Hoffmann et al.
patent: 4792547 (1988-12-01), Itoh et al.
patent: 5201932 (1993-04-01), Maywald et al.
patent: 5384305 (1995-01-01), Foster et al.
patent: 5780393 (1998-07-01), Newton
patent: 6201007 (2001-03-01), Ito et al.
patent: 6339045 (2002-01-01), Kanno et al.
patent: 6399607 (2002-06-01), Welch et al.
patent: 6645990 (2003-11-01), Askew et al.
patent: 7067507 (2006-06-01), Pulley et al.
patent: 7423147 (2008-09-01), Carruthers et al.
patent: 2003/0125339 (2003-07-01), Chen et al.
patent: 2004/0014744 (2004-01-01), Haviv et al.
patent: 2004/0019039 (2004-01-01), Dorwald et al.
patent: 2004/0110746 (2004-06-01), Apodaca et al.
patent: 2004/0224968 (2004-11-01), Seidelmann et al.
patent: 2006/0025404 (2006-02-01), Ancliff et al.
patent: 2006/0052597 (2006-03-01), Best et al.
patent: 2006/0178375 (2006-08-01), Ohtake et al.
patent: 2007/0066821 (2007-03-01), Allison et al.
patent: 2007/0167435 (2007-07-01), Mutahi et al.
patent: 2007/0219240 (2007-09-01), Cole et al.
patent: 2007/0281923 (2007-12-01), Keith et al.
patent: 2008/0045507 (2008-02-01), Allison et al.
patent: 1051888 (1979-04-01), None
patent: 817911 (1951-10-01), None
patent: 1902694 (1969-09-01), None
patent: 2514334 (1987-01-01), None
patent: 0134096 (1985-03-01), None
patent: 0143630 (1985-06-01), None
patent: 0488474 (1992-06-01), None
patent: 0089153 (1993-09-01), None
patent: 1388535 (2004-02-01), None
patent: 1396487 (2004-03-01), None
patent: 44-20347 (1969-09-01), None
patent: 46-37595 (1971-11-01), None
patent: 6-306051 (1994-11-01), None
patent: WO 84/04304 (1984-11-01), None
patent: WO 00/50391 (2000-08-01), None
patent: WO 00/76984 (2000-12-01), None
patent: WO 01/85715 (2001-11-01), None
patent: WO 02 12214 (2002-02-01), None
patent: WO 03/004480 (2003-01-01), None
patent: WO 03/037869 (2003-05-01), None
patent: WO 03/037891 (2003-05-01), None
patent: WO 03/066604 (2003-08-01), None
patent: WO 03/078398 (2003-09-01), None
patent: WO 03/082205 (2003-10-01), None
patent: WO 03/092686 (2003-11-01), None
patent: WO 2004/018428 (2004-03-01), None
patent: WO 2004/054973 (2004-07-01), None
patent: WO 2005/007644 (2005-01-01), None
patent: WO 2005/009976 (2005-02-01), None
patent: WO 2005/023247 (2005-03-01), None
patent: WO 2005/040144 (2005-05-01), None
Akhundov, R.A. et al.: “Synthesis and Psychotropic Activity of Amides of 2-aminonicotinic Acid”,Khimiko-Farmatsevticheskki Zhurnal, vol. 20, No. 1 (1986) pp. 48-50, Rumoscow, Database Beilstein 1993, Database accession No. 5702704 (CNR) BRN: 5598995, 5632883, 5764929, 5774681, (XP002344011).
Arrang, J-M. et al.: Auto-inhibition of Brain Histamine Release Mediated by a Novel Class (H3) of Histamine Receptor.Nature1983, 302, 832-837.
Ash, A.S.F et al.: Receptors Mediating Some Actions of Histamine.Br. J. Pharmac. Chemother. 1966, 27, 427-439.
Barnes, J.C. et al.: The Selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release In Vivo.Soc. Neurosci. Abstr. 1993, 19, 1813.
Black, J.W. et al.: Definition and Antagonism of Histamine H2-Receptors.Nature1972, 236, 385-390.
Buchi, von J. et al.: “Syntheses of Some 2-Dialkylaminoalkoxy-6-alkylaminopyridines and 2-dialkylaminoalkylamino-6-alkoxypyridines”,Helvetica Chimica Acta., vol. 48, No. 5 (1965) pp. 1216-1219, Chverlag Helvetica Chimica Acta. Basel, (XP009050917).
Foks et al.: “Pyrazine derivatives. III. Synthesis and tuberculostatic activity of 6-(N-methyllamino)-pyrazine-2-carboxylic acid derivatives”, Polish Journal of Pharmacology and Pharmacy, vol. 26, No. 5 (1974) pp. 537-543 (XP002355523)—Chemical Abstracts, Database accession No. 82:43345 (DN) RN 54409-12-0.
Foks et al, “Aminomethylation of pyridine- and pyrazinecarbothioamides. V. 6-Chloro- and 6-aminopyrazine-2-carbothioamides in the Mannich reaction”, ACTA Poloniae Pharmaceutica, vol. 33, No. 1 (1976) pp. 55-65 (XP002355524)—Chemical Abstracts, Database accession No. 86:72575 (DN).
Ganellin, C.R. et al.: Synthesis of Potent Non-Imidazole Histamine H3-Receptor Antagonists.Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.) 1998, 331, 395-404.
Highfield, J.A. et al.: “Preparative, Physico-Chemical and Cytotoxicity Studies of Prodrugs Activated in Hyposiz to Give Metal-Binding Analogues of Bleomycin”,Journal of the Chemical Society, Perkin Transactions 1, vol. 16 (1999) pp. 2343-2352, GB Chemical Society, Letchworth, (XP002337176).
Ichinose, M. et al.: Histamine H3-Receptors Modulate Nonadrenergic Noncholinergic Neural Bronchoconstriction in Guinea-Pig In Vivo.Eur. J. Pharmacol. 1989, 174(1), 49-55.
Imamura, M. et al.: Unmasking of Activated Histamine H3-Receptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release.J. Pharmacol. Exp. Ther. 1994, 271(3), 1259-1266.
Krause, M. et al.: Medicinal Chemistry of Histamine H3Receptor Agonists. InThe Histamine H3Receptor—A Target for New Drugs. Leurs, R.; Timmerman, H., Eds.; Elsevier: 1998; pp. 175-196.
Letavic, M.A. et al.: Recent Medicinal Chemistry of the Histamine H3Receptor. Prog. in Med. Chem., in press, 2006.
Leurs, R. et al.: The Medicinal Chemistry and Therapeutic Potentials of Ligands of the Histamine H3Receptor.Prog. Drug Res. 1995, 45, 107-165.
Lin, J-S. et al.: Involvement of Histaminergic Neurons in Arousal Mechanisms Demonstrated with H3-Receptor Ligands in the Cat.Brain Res. 1990, 523, 325-330.
Linney, I.D. et al.: Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3Receptor Antagonists.J. Med. Chem. 2000, 43(12), 2362-2370.
Lovenberg, T.W. et al.: Cloning and Functional Expression of the Human Histamine H3Receptor.Mol. Pharmacol. 1999, 55(6), 1101-1107.
MacDonald, S.J.F. et al.: Discovery of Further Pyrrolidine trans-Lactams as Inhibitors of Human Neutrophil Elastase (HNE) with Potential as Development Candidates and the Crystal Structure of HNE Complexed with an Inhibitor (GW475151).J.Med.Chem. 2002, 45(18), 3878-3890.
Machidori, H. et al.: Zucker Obese Rats: Defect in Brain Histamine Control of Feeding.Brain Res. 1992, 590, 180-186.
Mase, T. et al.: Synthesis of Muscarinic Receptor Antagonist via a Diastereoselective Michael Reaction, Selective Deoxyfluorination and Metal-Halogen Exchange Reaction.J. Org. Chem. 2001, 66, 6775-6786.
McLeod, R.L. et al.: Antimigraine and Sedative Activity of SCH 50971: A Novel Orally-Active Histamine H3Receptor Agonist.Soc. Neurosci. Abstr. 1996, 22, 2010.
Monti, J.M. et al.: Effects of Selective Activation or Blockade of the Histamine H3Receptor on Sleep and Wakefulness.Eur. J. Pharmacol. 1991, 205(3), 283-287.
Morisset, S. et al.: High Constitutive Activity of Native H3Receptors Regulates Histamine Neurons in Brain.Nature2000, 408, 860-864.
Ortho-McNeil Pharmaceutical, Inc.: (WO03050099); “Phenylalkynes to Treat Histamine-Mediated Conditions”,Expert Opinion on Therapeutic Patents, vol. 13, No. 11 (2003) pp. 1759-1762, (XP002337280).
Panula, P. et al. Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease.Soc. Neurosci. Abstr. 1995, 21, 1977.
Patani, G.A. et al.: Bioisosterism: A Rational Approach in Drug Design; Chem. Rev. (1996) 96: 3147-3176.
Pavia et al.: “N,N-Disubstittuted 6-Alkoxy-2-Pyridinamines as Anticonvulsant Agents”,Journal of the American Chemical Society, vol. 30, No. 7 (1987) pp. 1210-1214, US American Chemical Society, Washington DC, (XP002337175).
Phillips, J.G. et al.: Medicinal Chemistry of Histamine H3Receptor Antagonists. InThe Histamine H3Receptor—A Target for New Drugs. Leurs, R.; Timmerman, H., Eds.; Elsevier: 1998; pp. 197-222.
Reiner, J.E. et al.: Non-Covalent Thrombin Inhibitors Featuring P3-Heterocycles with1-Monocyclic Arginine Surrogates.Bioorg. Med. Chem. Lett. 2002, 12, 1203-1208.
Schlicker, E. et al.: The Moderate Affinity of Clozapine at H3Receptors Is Not Shared by Its Two Major M

Affiliated with

Also associated with

Rating

Isoxazole compounds as histamine H 3 modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Isoxazole compounds as histamine H 3 modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoxazole compounds as histamine H 3 modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2663753